MDR1 Checks Before Routine Treatment

If you own a small dog from a Russian breeding line, verify three things before any routine treatment: the dog's MDR1 (ABCB1) genotype, the exact active ingredient and dose in the product offered, and whether the breed's documented history includes herding or working lines where the mutation is more common. A breed standard tells you what a dog should look like; a genetic screening result tells you what this individual dog can safely metabolise. The two documents answer different questions and neither replaces the other.

Which small breeds descend from Russian breeding programmes?

Several breeds kept today as companions or small working dogs trace their development to Russian and Soviet kennels. The Russkiy Toy, recognised under FCI standard 352, was developed from small dogs kept in Russian towns and later formalised in the twentieth century. The Siberian Laika breeds, including the West Siberian Laika, come from hunting lines selected across Siberia. The Samoyed, the Borzoi, the Caucasian Shepherd and the Black Russian Terrier all have Russian or Soviet origins, though most are medium to large rather than small. For a French-reading owner who wants the breed histories, origins and functions set out in one place, the independent editorial review on Russian dog breeds covers the Russkiy Toy dossier, the Samoyed, the Borzoi, the Caucasian Shepherd, the Black Russian Terrier and the West Siberian Laika, with the FCI standard details and the Soviet-era breeding context.

Small size does not by itself predict MDR1 status. What matters is ancestry. Herding breeds and their crosses carry the highest published frequencies of the ABCB1 nonsense mutation, and any small dog with collie-type or herding ancestry in the pedigree deserves a genotype test before ivermectin-class drugs are used. A Russkiy Toy from companion lines is not a collie, but if the pedigree is unknown or includes a herding cross, treat the dog as untested until a laboratory says otherwise.

What should an owner check before accepting a routine antiparasitic treatment?

Routine does not mean risk-free. The word describes how often a drug is given, not how safe it is for every genotype.

Ask for the active ingredient, not the brand. Macrocyclic lactones are the class that matters most for MDR1-affected dogs. This includes ivermectin, milbemycin oxime, moxidectin, selamectin and doramectin. Many monthly heartworm preventives contain one of these at a dose that is safe for most MDR1-affected dogs, but the margin narrows sharply when the same molecule is used at the higher doses found in some mange or ear-mite products.

Check the dose against the dog's weight. Small breeds sit in a range where a tablet split for a 5 kg dog and a tablet split for a 12 kg dog can differ by a factor of two. Weigh the dog, not the breed average.

Check the route and the formulation. A spot-on, an oral chew and an injectable can carry very different systemic exposures even when the label names the same molecule.

Check what else the dog is receiving. Some combination products add an isoxazoline, an insect growth regulator or an antibiotic. Interactions and cumulative exposure are the owner's business because the owner is the one who will observe the dog afterwards.

Check the label for the species. Permethrin spot-ons sold for dogs are toxic to cats and are not interchangeable. Products formulated for large animals are not dose-scaled for a 3 kg companion.

Finally, ask what happens if the dog reacts. Know the signs of neurological toxicity: dilated pupils, tremors, ataxia, hypersalivation, disorientation. These can appear within hours. A dog with a known MDR1 mutation that shows any of them needs veterinary assessment the same day, not the next scheduled visit.

How does a breed standard differ from a genetic screening result?

A breed standard is a descriptive document. FCI standard 352, for example, sets out the Russkiy Toy's size range, coat varieties, colours and proportions. It is written by a breed club and approved by a kennel authority. It describes the population, not the individual, and it says nothing about which drugs a given dog can clear.

A genetic screening result is an individual laboratory finding. For MDR1 it reports one of three genotypes: clear (two normal copies), carrier (one mutated copy) or affected (two mutated copies). The affected genotype is the one associated with the severe neurological reactions to high-dose macrocyclic lactones and with altered handling of several other drugs, including some opioids, some chemotherapy agents and some antiemetics.

A dog can be perfect against its standard and affected for MDR1. A dog can be a poor show specimen and clear for MDR1. Neither result cancels the other. Owners sometimes assume that a pedigree, a health certificate from a breeder or a good veterinary examination substitutes for a genotype test. It does not. The test is a cheek swab or a blood sample sent to a laboratory, and the result is a document you can hand to any veterinarian who proposes a treatment.

Which drugs deserve a second look in MDR1-affected dogs

The published list is longer than most owners expect. High-dose ivermectin is the classic trigger. Others include milbemycin oxime at mange doses, moxidectin at high systemic exposure, some opioids such as loperamide at high doses and certain chemotherapy agents including vincristine and doxorubicin. Acepromazine and butorphanol have been reported to produce prolonged sedation in affected dogs. Anaesthetic protocols should be adjusted rather than avoided outright, because untreated pain and untreated disease carry their own risks.

For a small breed, the practical rule is that any drug with a narrow therapeutic index and a central nervous system target deserves a genotype check first. That is a short list, and a veterinarian can review it in a few minutes if the owner brings the test result to the appointment.

A short pre-treatment checklist

Before saying yes to a routine product, confirm the following in writing or on the label:

• The dog's MDR1 genotype, or a plan to test before the first high-dose macrocyclic lactone.
• The active ingredient and its concentration.
• The dose in milligrams per kilogram for this dog's current weight.
• The route of administration and whether it is repeated.
• Every other drug, supplement or preventive the dog is already taking.
• The name and phone number of the veterinary practice that will see the dog if a reaction occurs.

This list takes ten minutes. It prevents the most common avoidable adverse event in MDR1-affected dogs, which is a high-dose macrocyclic lactone given to an untested animal.

Why Russian breed history is part of the picture

Breed origin is not a substitute for a genotype test, but it is useful context. Dogs developed for herding, guarding or hunting were often selected for working ability rather than for drug tolerance, and the ABCB1 mutation can persist in a closed population for generations without obvious signs until the wrong drug is used. Knowing whether a small companion breed shares ancestry with herding lines, and knowing what the standard does and does not say, helps an owner ask better questions at the clinic. The breed histories, the FCI standard details and the practical ownership notes collected by Chien Russe are a reasonable starting point for that background reading, and they pair well with a laboratory result for the individual dog in front of you.

Reference: FCI Russkiy Toy standard 352; NCBI GeneReviews.